MX2010004899A - Conjugados de neurturina novedosos para uso farmaceutico. - Google Patents

Conjugados de neurturina novedosos para uso farmaceutico.

Info

Publication number
MX2010004899A
MX2010004899A MX2010004899A MX2010004899A MX2010004899A MX 2010004899 A MX2010004899 A MX 2010004899A MX 2010004899 A MX2010004899 A MX 2010004899A MX 2010004899 A MX2010004899 A MX 2010004899A MX 2010004899 A MX2010004899 A MX 2010004899A
Authority
MX
Mexico
Prior art keywords
pharmaceutical use
conjugates
neurturin conjugates
neurturin
novel
Prior art date
Application number
MX2010004899A
Other languages
English (en)
Spanish (es)
Inventor
Matthias Austen
Marcus Geese
Martin Schneider
Rainer Mussmann
Friedrich Harder
Thomas Siegmund
Original Assignee
Develogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen Ag filed Critical Develogen Ag
Publication of MX2010004899A publication Critical patent/MX2010004899A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2010004899A 2007-11-05 2008-11-05 Conjugados de neurturina novedosos para uso farmaceutico. MX2010004899A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07021493 2007-11-05
PCT/EP2008/009320 WO2009059755A2 (en) 2007-11-05 2008-11-05 Novel neurturin conjugates for pharmaceutical use

Publications (1)

Publication Number Publication Date
MX2010004899A true MX2010004899A (es) 2010-09-07

Family

ID=40521395

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004899A MX2010004899A (es) 2007-11-05 2008-11-05 Conjugados de neurturina novedosos para uso farmaceutico.

Country Status (17)

Country Link
US (3) US9029323B2 (enExample)
EP (1) EP2217282A2 (enExample)
JP (2) JP2011503019A (enExample)
KR (2) KR20150139982A (enExample)
CN (2) CN104288775A (enExample)
AU (1) AU2008324426B2 (enExample)
BR (1) BRPI0819220A2 (enExample)
CA (1) CA2742839A1 (enExample)
CO (1) CO6280503A2 (enExample)
CR (1) CR11406A (enExample)
EA (1) EA201070484A1 (enExample)
IL (1) IL205290A (enExample)
MX (1) MX2010004899A (enExample)
NZ (1) NZ585262A (enExample)
SG (1) SG185946A1 (enExample)
WO (1) WO2009059755A2 (enExample)
ZA (1) ZA201003227B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222070A1 (en) 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
DK1694354T3 (da) 2003-11-27 2009-10-26 Develogen Ag Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin
BR112012009801A8 (pt) * 2009-10-30 2016-08-30 Cns Therapeutics Inc Polipeptídeo neurturina e variante de neurturina
US9127083B2 (en) 2009-10-30 2015-09-08 Ntf Therapeutics, Inc. Neurturin molecules
US8445432B2 (en) 2009-10-30 2013-05-21 Ntf Therapeutics Inc Neurturin molecules
US8742677B2 (en) * 2010-01-11 2014-06-03 System General Corp. LED drive circuit with a programmable input for LED lighting
CN102453725B (zh) * 2010-11-02 2014-06-11 杭州纽龙生物科技有限公司 一种重组载体、包含该重组载体的重组菌株及制备方法
JP6051378B2 (ja) * 2011-05-02 2016-12-27 国立大学法人 熊本大学 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
JP2003524381A (ja) * 1998-09-22 2003-08-19 ユニヴァーシティ オブ メリーランド，ボルチモア システインノット成長因子ミュータント
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US20050222070A1 (en) * 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
EP2275118A3 (en) 2002-05-29 2011-10-19 DeveloGen Aktiengesellschaft Pancreas-specific proteins
ES2342397T3 (es) * 2003-10-20 2010-07-06 Nsgene A/S Vector virico para su uso en terapia genica in vivo de la enfermedad de parkinson.
DK1694354T3 (da) * 2003-11-27 2009-10-26 Develogen Ag Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin
EP1872790A1 (en) * 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft New formulation for increasing bioavailability of neurturin

Also Published As

Publication number Publication date
EP2217282A2 (en) 2010-08-18
IL205290A (en) 2014-01-30
WO2009059755A2 (en) 2009-05-14
BRPI0819220A2 (pt) 2019-02-26
CR11406A (es) 2010-10-25
US20130231283A1 (en) 2013-09-05
US20160060317A1 (en) 2016-03-03
CN101848735A (zh) 2010-09-29
JP2015057384A (ja) 2015-03-26
ZA201003227B (en) 2011-03-30
US20110003741A1 (en) 2011-01-06
CO6280503A2 (es) 2011-05-20
JP2011503019A (ja) 2011-01-27
CN104288775A (zh) 2015-01-21
KR20100098619A (ko) 2010-09-08
KR20150139982A (ko) 2015-12-14
SG185946A1 (en) 2012-12-28
US9029323B2 (en) 2015-05-12
AU2008324426B2 (en) 2014-03-27
NZ585262A (en) 2012-06-29
EA201070484A1 (ru) 2011-04-29
CA2742839A1 (en) 2009-05-14
AU2008324426A1 (en) 2009-05-14
IL205290A0 (en) 2010-12-30
WO2009059755A3 (en) 2009-09-24
CN101848735B (zh) 2014-07-23

Similar Documents

Publication Publication Date Title
EP3381445A3 (en) Aqueous formulation of antibody stablised by antioxidants for parenteral administration
WO2010069532A8 (en) Antibodies against human angiopoietin 2
WO2010000877A3 (en) Formulation with irritation reducing action comprising bisabolol and [6]-paradol
EP3406347A3 (en) Xten conjugate compositions and methods of making same
IL229304A (en) Compounds 1 ', 3' - Imaging Converts - 4 - Phenyl - 3, 4, 5, 6 - Tetrahydro - 2h, 1'h, [1, 4 '] Bipyridinyl - 2' - lozenges, pharmaceutical preparations containing them and their use
MY156951A (en) Micromirs
IL189008A (en) History of 1-Naphthalenyl-3-azabicyclo [0.1.3] hexane
WO2008006528A3 (en) Pharmaceutical compositions comprising levetiracetam
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
WO2007090393A3 (de) Pharmazeutische zubereitung auf basis vom mikrotabletten
HUE049976T2 (hu) N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói
WO2009059755A3 (en) Novel neurturin conjugates for pharmaceutical use
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2010021607A3 (en) Pharmaceutical formulation
IL185197A0 (en) Ophthalmological pharmaceutical compositions
WO2010046061A3 (de) Kosmetische und/oder pharmazeutische zubereitungen
WO2006095029A3 (en) Di-polymer protein conjugates and processes for their preparation
WO2009130422A3 (fr) N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog
MX2010001243A (es) Composicion anti-inflamatoria.
WO2011014003A3 (en) (+)-3-hydroxymorphinan derivatives as neuroprotectants
WO2009053628A3 (fr) Nouveaux composes, préparation et utilisations
WO2007100668A3 (en) Antidepressant prodrugs
EP2371379A3 (en) New formulation for increasing bioavailability of neurturin
WO2007104768A3 (en) Di-polymer protein conjugates and processes for their preparation
WO2011039675A3 (en) Latrepirdine transdermal therapeutic dosage forms

Legal Events

Date Code Title Description
FG Grant or registration